Mediamedic/LinkedIn
Sep 29, 2025, 16:19
Xue Feng Presented Her Work on AAV Vector–Based Gene Therapy
Mediamedic shared a post on LinkedIn:
“ISEH 2025 | Professor Xue Feng: AAV Gene Therapy Transforming Hemophilia B Treatment in China
At the 54th Annual Scientific Meeting of ISEH in Kumamoto, Japan, Professor Xue Feng (Institute of Hematology & Blood Diseases Hospital, CAMS) presented her work on AAV vector–based gene therapy expressing Factor IX Padua for Hemophilia B.
In an exclusive interview with Oncology Frontier – Hematology Frontier, she shared the science behind this innovative approach, its clinical potential, and the future of gene therapy development in China.”
Stay updated with Hemostasis Today.
-
Jan 11, 2026, 11:00Benjamin YQ Tan on Impacts of Early Cognitive and Psychological Statuses Post-Stroke
-
Jan 11, 2026, 10:46Salvador Payán Pernía: Leukodepletion Reduces Microplastic Burden in Red Blood Cell Concentrates
-
Jan 11, 2026, 10:36Mariasanta Napolitano on Pregnancy and Delivery Outcomes in Women with Hemophilia
-
Jan 11, 2026, 10:19Quick Explanation of Types of Blood Transfusion from John Amako
-
Jan 11, 2026, 06:18Filippo Cademartiri on Why Vascular Health Is Cognitive Health
-
Jan 11, 2026, 06:01Maira Dastgir N on Cannabis-Induced Ischemic Stroke
-
Jan 11, 2026, 05:51Nishant K Mishra on Preventing Post-Stroke Seizures
-
Jan 11, 2026, 05:41Indunil Karunarathna on CSF Xanthochromia in SAH
-
Jan 11, 2026, 05:22Mitchell Elkind on The New York Times Brain Health Challenge: Food Is Brain Medicine!